Answers are grounded in this paper and cite their sources.
Background Monocarboxylate transporter 8 (MCT8) deficiency is a rare neurodevelopmental and metabolic disorder caused by mutations in thyroid hormone transporter MCT8. Triac Trial I showed that T3 analogue Triac effectively alleviates peripheral thyrotoxicosis. However, the effects of Triac on patient-centered outcome measures are unknown. Here, we investigated relevant health outcomes, from a caregiver's perspective, that have direct impacts on the daily lives of patients and families. Methods We performed post-hoc analyses on caregiver-reported patient-centered outcome measures from Triac Trial I. This trial was an international, multicenter, phase II, single-arm, open-label trial conducted between October 2014 and June 2017. Adult and paediatric patients who completed ≥12 months of treatment with Triac were included. Semi-structured interviews were held with caregivers during all visits, assessing disease specific features and their changes. The primary objective was to identify the caregiver-reported features that showed the most prominent changes following 12 months of Triac treatment. This question ("What are the most prominent changes that the parents have observed upon Triac treatment?") was phrased open-ended to caregivers, allowing multiple observations, including both positive and negative responses. Secondary objectives were changes in syndrome-specific features and willingness to continue Triac treatment. The Triac Trial I was registered with ClinicalTrials.gov (NCT02060474). Findings In total, 40 patients were included. The median age at baseline was 7.1 years (range 1.6–66.8) and all participants were male. Caregivers of 39/40 patients (98%) reported a median of three (range 1–10) prominent changes on this open-ended question. Data on the most prominent change was not available for one patient. The most prominent changes reported by caregivers were improved interaction (23/39), alertness (16/39), motor skills (13/39), body weight (11/39) and sleep (8/39). Compared with baseline, excessive perspiration (9% vs. 49%, p < 0.0004) and constipation (42% vs. 61%, p < 0.023) were reportedly reduced after 12 months of treatment, and the proportion of patients with a sleep pattern perceived by caregivers as ‘normal' increased (92% vs. 67%, p < 0.041). Caregivers of all patients (40/40) preferred Triac continuation after trial completion. Interpretation In this exploratory post-hoc analysis of paediatric and adult patients with MCT8 deficiency, Triac improved caregiver-reported outcomes that are relevant to the daily lives of patients assessed. Although we did not assess caregiver-reported outcomes using validated clinical criteria, these data support existing positive findings of Triac on clinical and biochemical outcomes, recent approval by the European Medicines Agency and US Food and Drug Administration, and support beneficial effects on relevant disease features.
No takes yet. Share an insight, caveat, or question.
Freund et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: